ZLAB vs LEGN vs ZYME vs CAN vs RCUS

For growth investors, Canaan Inc.

(CAN) is the stronger pick with 96. 7% revenue growth year-over-year, versus -4. 3% for Arcus Biosciences, Inc. (RCUS). Analysts rate Zai Lab Limited (ZLAB) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Legend Biotech Corporation (LEGN) delivered a total return of -0.

0%, compared to -92. 3% for Canaan Inc. (CAN). Over 10 years, the gap is even starker: ZYME returned +104. 6% versus CAN's -90. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Legend Biotech Corporation (LEGN) is the lower-risk stock at 0.

77β versus Canaan Inc. 's 4. 41β — meaning CAN is approximately 475% more volatile than LEGN relative to the S&P 500. On balance sheet safety, Zymeworks Inc. (ZYME) carries a lower debt/equity ratio of 7% versus 41% for Legend Biotech Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Canaan Inc.

(CAN) is pulling ahead at 96. 7% versus -4. 3% for Arcus Biosciences, Inc. (RCUS). On earnings-per-share growth, the picture is similar: Canaan Inc. grew EPS 51. 1% year-over-year, compared to -66. 0% for Legend Biotech Corporation. Over a 3-year CAGR, LEGN leads at 106. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Legend Biotech Corporation (LEGN) is the more profitable company, earning -28.

8% net margin versus -142. 9% for Arcus Biosciences, Inc. — meaning it keeps -28. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LEGN leads at -13. 3% versus -156. 3% for RCUS. At the gross margin level — before operating expenses — RCUS leads at 96. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Zymeworks Inc.

(ZYME) trades at 22. 4x forward P/E versus 118. 1x for Legend Biotech Corporation — 95. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CAN: 336. 9% to $2. 25.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Legend Biotech Corporation (LEGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

77)). Canaan Inc. (CAN) carries a higher beta of 4. 41 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LEGN: -22. 8%, CAN: -90. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ZLAB (Healthcare) and LEGN (Healthcare) and ZYME (Healthcare) and CAN (Technology) and RCUS (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ZLAB is a small-cap high-growth stock; LEGN is a small-cap high-growth stock; ZYME is a small-cap high-growth stock; CAN is a small-cap high-growth stock; RCUS is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.